Search Results
Your search for ,wHo matches 21223 pages
Showing 14551 - 14600Survival Benefit Reported With Maintenance Olaparib in Platinum-Sensitive Recurrent Serous Ovarian Cancer With BRCA Mutation
Maintenance olaparib (Lynparza) appeared to be associated with an overall survival benefit vs placebo in women with platinum-sensitive serous ovarian cancer and BRCA1 and BRCA2 mutations, according to an updated analysis of a phase II trial reported in The Lancet Oncology by Ledermann et al....
ASCO, ASTRO, and SSO Issue Joint Update to Guideline on Postmastectomy Radiotherapy for Women With Breast Cancer
Earlier this month, ASCO, in collaboration with the American Society for Radiation Oncology (ASTRO) and the Society for Surgical Oncology (SSO), jointly issued an update to a clinical practice guideline for physicians treating women with breast cancer who have undergone a mastectomy. The update...
Lung Cancer Specialist Shares Clinical Pearls for Managing Stage IIIA Non–Small Cell Lung Cancer
Clinicians face a number of questions in evaluating and treating patients with stage IIIA non–small cell lung cancer (NSCLC). One expert in the field, Rafael Santana-Davila, MD, reviewed key issues in managing this disease in the Journal of Oncology Practice (JOP). The ASCO Post asked Dr....
Updated USPSTF Guidelines for Colorectal Cancer Screening: More Methods, More Challenges for Patients and Providers Alike
As reviewed in this issue of The ASCO Post, the U.S. Preventive Services Task Force (USPSTF) recently updated its guidelines for colorectal cancer screening1 from 2008 and has now included seven acceptable strategies, including direct-visualization modalities (ie, endoscopy and computed tomography...
New USPSTF Recommendations for Colorectal Cancer Screening
As reported in JAMA, the U.S. Preventive Services Task Force (USPSTF) has issued new recommendations for colorectal cancer screening.1 In brief, the USPSTF recommends colorectal cancer screening starting at age 50 years and continuing until age 75 years (grade A recommendation = “The USPSTF...
Testosterone-Related Genetic Mutation Associated With Poorer Survival in Prostate Cancer
A collaborative Cleveland Clinic–Mayo Clinic team of researchers has shown for the first time that patients with advanced prostate cancer are more likely to die earlier of their disease if they carry a specific testosterone-related genetic abnormality. The findings, published by Hearn et al in The...
FDA Approves Ofatumumab in Combination With Fludarabine and Cyclophosphamide for Relapsed CLL
The U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application for the use of ofatumumab (Arzerra) in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL). The application, which...
ASH Presents Charles Mullighan, MBBS (Hons), MD, With the 2016 William Dameshek Prize
The American Society of Hematology (ASH) will present the 2016 William Dameshek Prize to Charles Mullighan, MBBS (Hons), MD, of St. Jude Children’s Research Hospital, for his leadership in defining the landscape of genetic alterations of acute lymphocytic leukemia (ALL), which has provided...
Novel Agents on the Horizon in Lymphoma
Attendees at the 2016 Pan Pacific Lymphoma Conference held July 18–22 in Koloa, Hawaii, got a peek at early data for a number of novel agents in the treatment of various lymphoma subtypes. The ASCO Post captured these findings. Denintuzumab Mafodotin in Diffuse Large B-Cell Lymphoma Denintuzumab...
Routine PET Surveillance Discouraged in Large Cell Lymphoma
There is no role for routine imaging as a means of following patients with large cell lymphoma, according to Bruce D. Cheson, MD, Deputy Chief of Hematology-Oncology and Professor of Medicine at Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC. “Routine...
Enhanced Survival With Implantable Scaffolds That Capture Metastatic Breast Cancer Cells in Vivo
A small device implanted under the skin may improve breast cancer survival by catching cancer cells, slowing the development of metastatic tumors in other organs, and allowing time to intervene with surgery or other therapies. These findings, reported by Rao et al in Cancer Research, suggest a path ...
Specimen Margin Tops Frozen Margin as Prognostic Marker in Oral Cancer Surgery
Intraoperative frozen margins from the tumor bed help to assess the prognosis of oral cancer, but the permanent specimen margin remains king, according to a retrospective cohort study reported at the 9th International Conference on Head and Neck Cancer.1 Results indicated that the rate of local...
Expert Point of View: Benjamin L. Judson, MD
“This (adverse cardiac effects of chemotherapy) is a difficult problem to address because the side effects of chemotherapy in terms of its impact on the heart show up many years, sometimes decades, later. So that makes it harder to study and treat. It’s a real problem,” commented session...
Testosterone Therapy May Be Cardioprotective in Patients Undergoing Chemotherapy
The anabolic hormone testosterone may lessen the early adverse cardiovascular effects of chemotherapy and chemoradiation for advanced or recurrent cancer, according to a randomized controlled trial reported at the 9th International Conference on Head and Neck Cancer.1 Among the patients studied,...
Reducing Drug Costs by Increasing Science-Driven Drug Discovery
For several years now, the American health-care system has been undergoing a transformation. Innovative ideas are being explored, new systems continue to be created, and millions of lives have been impacted. As health-care providers and research engines, academic institutions have an opportunity...
Immune Checkpoint Inhibitors March to First-Line Treatment in Advanced NSCLC
For the majority of patients who are diagnosed with advanced-stage non–small cell lung cancer (NSCLC), platinum-based doublets have been the standard of care for over 30 years. Recently, the immune checkpoint inhibitors nivolumab (Opdivo) and pembrolizumab (Keytruda) demonstrated superior survival ...
Early Studies Examine Response of CML-Initiating Cells to Ezh2 Inhibition
Although targeted drugs like imatinib (Gleevec) have revolutionized the treatment of chronic myelogenous leukemia (CML), patients generally must take them for the rest of their lives and may cease benefiting from them over time. New research conducted by scientists at Dana-Farber Cancer Institute...
Decisional Regret After Initial Treatment Decisions Among Parents of Children With Cancer
Racial/ethnic minority parents were more likely to express regret about initial cancer treatment decisions for their children, according to a study reported in the Journal of Clinical Oncology. Mack et al found that factors associated with less decisional regret included receiving high-quality...
Adolescent Girls With Leukemia May Not Be Screened for Pregnancy Before Beginning Chemotherapy
A new study indicates that adolescent females with acute leukemia have low rates of pregnancy screening prior to receiving chemotherapy that can cause birth defects. These findings were published by Rao et al in Cancer. Although many chemotherapy drugs can cause birth defects, there are no...
Good Outcome Reported With Unrelated-Donor Cord Blood Transplantation in Patients With Minimal Residual Disease
Survival with hematopoietic cell transplantation (HCT) from unrelated cord-blood donors was at least as good as that with HLA-matched unrelated donors and better than that with HLA-mismatched unrelated donors in patients with acute leukemia or myelodysplastic syndrome who had pretransplantation...
Vice President Biden Announces New Steps to Improve Clinical Trials Essential to Advancing the Cancer Moonshot
Today, Vice President Joe Biden announced a series of new steps focused on increasing access to information about clinical trials and improving the efficiency of our clinical research system. These steps include making it easier for participants to find clinical trial opportunities as quickly as...
American Association for Cancer Research Releases 2016 Cancer Progress Report
Federally funded research continues to spur progress against cancer; however, accelerating the pace of progress will require robust, sustained, and predictable annual funding increases for the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Food and Drug...
Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer
A drop in the number of cancer cells detected in a patient’s blood could be the best indicator yet as to whether treatment for prostate cancer is working. A new study, published by Lorente et al in European Urology, shows that a 30% decline in a patient’s numbers of circulating tumor...
Similar 10-Year Survival Reported With Active Monitoring, Surgery, or Radiotherapy for PSA-Detected Localized Prostate Cancer
In a UK trial (ProtecT) reported in The New England Journal of Medicine, Hamdy et al found no significant differences in prostate cancer–specific or overall mortality among men with localized prostate cancer detected by prostate-specific antigen (PSA) testing who underwent active monitoring,...
PSA Failure Seems to Be Linked to Poorer Survival in Men With Unfavorable-Risk Prostate Cancer and No/Minimal Comorbidity
In an analysis of a clinical trial population reported in the Journal of Clinical Oncology, Giacalone et al found that prostate-specific antigen (PSA) failure was associated with an increased risk of mortality among men with unfavorable-risk prostate cancer who had no or minimal comorbidity burden. ...
Preclinical Study Finds Tamoxifen Resistance Linked to High Estrogen Levels in Utero
An animal study suggests that resistance to tamoxifen therapy in some estrogen receptor–positive breast cancers may originate from in utero exposure to endocrine-disrupting chemicals. The study provides a new path forward in human research, as about half of the breast cancers treated with...
Shorter Survival Reported With Neoadjuvant Chemotherapy vs Primary Reductive Surgery in Stage IIIC Ovarian Cancer
Neoadjuvant chemotherapy was associated with shorter survival vs primary cytoreductive surgery in patients with stage IIIC ovarian cancer, according to a multi-institute observational study reported by Meyer et al in the Journal of Clinical Oncology. The study involved 1,538 women with stage IIIC...
Chinese Journal of Cancer Extends Deadline for Submission of Most Important Questions in Cancer Research and Clinical Oncology
The Chinese Journal of Cancer (CJC) is soliciting the 150 most important questions in cancer research and clinical oncology from cancer researchers around the world. The editors of CJC believe this will help provide important insights and guidance in future efforts to advance cancer research...
Palliative Care 2016: Attitudes of ASTRO Members Toward Palliative and Supportive Care in the United States
Radiation oncologists are frequently involved in providing palliative and supportive care for patients with advanced cancers through delivery of palliative radiation. Whether they are confident in their ability to assess and initiate treatments for pain, nonpain, and psychosocial distress is...
Study Finds HIV Infection Linked to Reduced Survival Among Women With Cervical Cancer in Botswana
Despite access to and use of antiretroviral therapy, HIV (human immunodeficiency virus) infection was associated with reduced survival in women with cervical cancer in Botswana, according to a study reported by Dryden-Peterson et al in the Journal of Clinical Oncology. Study Details The study...
Palliative Care 2016: Usage of Oregon’s Death With Dignity Act
In 1997, Oregon enacted a voter initiative allowing terminally ill residents to self-administer physician-prescribed medication to end their lives called the Oregon Death With Dignity Act (ORDWDA). Statute requires prescriptions written for lethal medications be reported; the state also collects...
Early FDG-PET and Volumetric Analysis May Be Best Predictors of Benefit in Ewing Sarcoma
In a study reported in the Journal of Clinical Oncology, Koshkin et al found that among anatomic and functional imaging modalities, volumetric analysis and outcome with early 18F-fluorodeoxyglucose (FDG)–positron-emission tomography (PET) were the best predictors of benefit in patients with...
Study Finds Wide Variation in Breast Density Assessments Among Radiologists
A large observational study examining the variation in breast density assessment among radiologists in clinical practice has found a wide variation—from 6.3% to 84.5%—in the percentage of mammograms rated as showing dense breasts, which persisted after adjusting for patient characteristics. The...
Randy L. Wei, MD, PhD, on Radiation Oncologists and Palliative Care
Randy L. Wei, MD, PhD, of the University of California, Irvine, discusses findings from a survey that focused on ASTRO members who assessed their ability to deliver palliative and supportive care, and their access to continuing medical education on the topic (Abstract 105).
Sriram Yennu, MD, on Patient Perception of Curability
Sriram Yennu, MD, of The University of Texas MD Anderson Cancer Center, discusses findings from a study of an international cohort of patients with advanced cancer who received palliative care. Nearly half the patients incorrectly believed their cancer was curable (Abstract 5).
Jennifer S. Temel, MD, on The Changing Conversation Around Prognostication
Jennifer S. Temel, MD, of Massachusetts General Hospital, discusses increasing prognostic uncertainty in light of targeted treatments and immunotherapies, and the difficulty predicting who will benefit.
ECOG-ACRIN Group Co-Chair Robert L. Comis, MD, to Step Down in 2019
The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) announced that Robert L. Comis, MD, Professor of Medicine at Drexel University, is stepping down from his position as Group Co-Chair of the organization. His departure, effective February 28, 2019, will coincide with the end of ECOG-ACRIN’s current ...
Limited Access to Radioimmunotherapy in the Community Setting May Lead to Extinction of a Unique Lymphoma Treatment
I am writing to ask the ASCO community for help in addressing a policy decision by the Nuclear Regulatory Commission (NRC) that requires oncologists to take a 700-hour course (on the full range of nuclear medicines) to give one medicine to their patients: prepackaged radioimmunotherapy. It’s...
Cyclophosphamide/Methotrexate Maintenance Shows No Benefit in Hormone Receptor–Negative Breast Cancer, but Subgroup May Benefit
Low-dose oral cyclophosphamide plus methotrexate maintenance therapy yielded no disease-free survival benefit in women with hormone receptor–negative early breast cancer, according to the phase III International Breast Cancer Study Group (IBCSG) 22-00 trial. Some evidence of benefit was observed in ...
Impact of Adherence to Cancer Prevention Guidelines on Diet, Physical Activity on Cancer Risk and Mortality
According to the American Cancer Society’s 2016 Cancer Facts & Figures, behaviors such as poor diet choices, physical inactivity, excess alcohol consumption, and unhealthy body weight account for about 20% of all cancers diagnosed in the United States and likely could be prevented with...
Immunotherapy Is Not a Replacement Therapy
Some patients who ask about immunotherapy do so because they don’t want to get chemotherapy. Immunotherapy “is not a replacement yet, especially for chemotherapy, which has a track record of curing cancer,” Anas Younes, MD, medical oncologist and Chief of the Lymphoma Service at Memorial Sloan...
FDA Warns of Risks Associated With the Use of Tests Marketed as ‘Ovarian Screening’
The U.S. Food and Drug Administration (FDA) is alerting women about the risks associated with the use of tests being marketed as ovarian cancer screening tests. The agency is especially concerned about delaying effective preventive treatments for women who show no symptoms but who are still at...
Media Reports of Dramatic Responses to Immunotherapy After All Else Fails May Prompt Patients to Seek It Out
Immunotherapy has received “a lot of attention, mainly because of the media coverage,” Anas Younes, MD, medical oncologist and Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center in New York, said in an interview with The ASCO Post. “Many patients inquire, not about a specific...
Electronic Health Record Data May Help Identify Older Patients at Highest Risk of Early Death From Chemotherapy for Diffuse Large B-Cell Lymphoma
Although diffuse large B-cell lymphoma (DLBCL) is a curable disease in most patients aged 65 years or older, these patients are also at higher risk of chemotherapy-related death within the first 30 days of treatment. To quantify the risk of early fatality and identify risk factors, researchers led ...
Study Suggests Benefit of Adjuvant Radiation Therapy but Not Chemotherapy in Some Patients With Merkel Cell Carcinoma
In an analysis of National Cancer Data Base data reported in the Journal of the National Cancer Institute, Bhatia et al found that adjuvant radiotherapy was associated with a survival benefit in patients with stage I and II but not stage III Merkel cell carcinoma, with no benefit of adjuvant...
I’ve Survived Two Cancers
In 2012, my husband, Robert, and I were looking forward to starting the next phase of our lives and were feeling excited about the future. Although only in our 50s, we had decided to retire early from our full-time careers, move to our cabin in Hayward, Wisconsin, and find less stressful part-time ...
American Cancer Society Cancer Action Network Report Shows States Are Making Progress Implementing Policies to Reduce Toll of Cancer
While a majority of states are still missing important opportunities to pass and implement legislative solutions proven to prevent and fight cancer, progress is being made to move the nation closer to ending cancer as we know it, according to a report recently released by the American Cancer...
Oncologist’s Guilt
The best part of my day is hearing that little voice yell, “It’s Momma!” as my son rushes to greet me with a hug. It is humbling, and sometimes terrifying, to realize that I brought a little person into the world who is completely dependent on my husband and me for survival. Few would argue...
American Society of Hematology Recognizes Laurence Boxer, MD, and Ralph Nachman, MD, for Outstanding Mentorship
The American Society of Hematology (ASH) will honor Laurence Boxer, MD, and Ralph Nachman, MD, with 2016 Mentor Awards at the 58th ASH Annual Meeting and Exposition in San Diego, California, for their sustained, outstanding commitment to the training and career development of early-career...
New SSO, ASTRO, ASCO Joint Ductal Carcinoma in Situ Consensus Guideline Could Curb Unnecessary Breast Surgery and Reduce Health-System Costs
Three leading national cancer organizations have issued a consensus guideline for physicians treating women who have ductal carcinoma in situ treated with breast-conserving surgery with whole-breast irradiation. The new guideline has the potential to save many women from unnecessary surgeries,...
